Effects of empagliflozin on markers of calcium and phosphate homeostasis in patients with type 2 diabetes - Data from a randomized, placebo-controlled study.

Bone Rep · 2022 · PMC8857445 · PMID 35242892

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

A previous study with dapagliflozin reported a nonsignificant trend in reduction of 1,25(OH) 2 D ( de Jong et al., 2019 ).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.